MCID: EPL164
MIFTS: 66

Epilepsy malady

Categories: Neuronal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Epilepsy

Aliases & Descriptions for Epilepsy:

Name: Epilepsy 12 24 51 52 41 3 42 14 69
Epileptic Syndrome 12
Epilepsy Syndrome 12

Classifications:



Summaries for Epilepsy

NINDS : 51 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Epilepsy, also known as epileptic syndrome, is related to idiopathic generalized epilepsy and epilepsy, generalized, with febrile seizures plus, type 5, and has symptoms including back pain, headache and pain. An important gene associated with Epilepsy is EPM2A (EPM2A, Laforin Glucan Phosphatase), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Lacosamide and Lamotrigine have been mentioned in the context of this disorder. Affiliated tissues include temporal lobe, brain and testes, and related phenotypes are Resistant to vaccinia virus (VACV-A4L) infection and behavior/neurological

Disease Ontology : 12 A brain disease that is characterized by the occurrance of at least two unprovoked seizures resulting from a persistent epileptogenic abnormality of the brain that is able to spontaneously generate paroxysmal activity and typically manifested by sudden brief episodes of altered or diminished consciousness, involuntary movements, or convulsions.

MedlinePlus : 41 epilepsy is a brain disorder that causes people to have recurring seizures. the seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. people may have strange sensations and emotions or behave strangely. they may have violent muscle spasms or lose consciousness. epilepsy has many possible causes, including illness, brain injury, and abnormal brain development. in many cases, the cause is unknown. doctors use brain scans and other tests to diagnose epilepsy. it is important to start treatment right away. there is no cure for epilepsy, but medicines can control seizures for most people. when medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. special diets can help some children with epilepsy. nih: national institute of neurological disorders and stroke

Wikipedia : 71 Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures... more...

Related Diseases for Epilepsy

Diseases in the Epilepsy family:

Benign Familial Infantile Epilepsy Depdc5-Related Epilepsy

Diseases related to Epilepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 952)
id Related Disease Score Top Affiliating Genes
1 idiopathic generalized epilepsy 33.3 LGI1 POLG SCN1A
2 epilepsy, generalized, with febrile seizures plus, type 5 33.3 CACNB4 CHRNA4 CSTB EFHC1 GABBR1 GABRA1
3 early onset absence epilepsy 33.0 GABRG2 SCN1A SCN1B
4 scn1a-related seizure disorders 31.5 EPM2A NHLRC1
5 gingivitis 30.1 CSTB EPM2A GABRG2 SCN1A SCN1B
6 benign epilepsy with centrotemporal spikes 12.2
7 generalized epilepsy with febrile seizures plus 12.1
8 childhood absence epilepsy 12.1
9 epilepsy-aphasia spectrum 12.1
10 epilepsy, progressive myoclonic 2b 12.1
11 photosensitive epilepsy 12.1
12 epilepsy, pyridoxine-dependent 12.1
13 temporal lobe epilepsy 12.1
14 epilepsy, focal, with speech disorder and with or without mental retardation 12.1
15 autosomal dominant nocturnal frontal lobe epilepsy 12.1
16 progressive myoclonus epilepsy 12.1
17 focal epilepsy 12.0
18 epilepsy, progressive myoclonic 3, with or without intracellular inclusions 12.0
19 benign familial infantile epilepsy 12.0
20 ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant 12.0
21 myoclonic epilepsy associated with ragged-red fibers 12.0
22 autosomal dominant partial epilepsy with auditory features 12.0
23 spinal muscular atrophy with progressive myoclonic epilepsy 12.0
24 epilepsy, progressive myoclonic 7 12.0
25 epilepsy, juvenile myoclonic 5 12.0
26 progressive myoclonus epilepsy, lafora type 12.0
27 epilepsy, progressive myoclonic 5 12.0
28 myoclonic epilepsy, infantile, familial 12.0
29 epilepsy, progressive myoclonic 6 12.0
30 epilepsy, idiopathic generalized 11 12.0
31 prickle1-related progressive myoclonus epilepsy with ataxia 12.0
32 myoclonic astatic epilepsy 12.0
33 epilepsy, juvenile absence 1 12.0
34 epilepsy, nocturnal frontal lobe, 1 12.0
35 centrotemporal epilepsy 12.0
36 epilepsy, familial temporal lobe, 1 12.0
37 epilepsy, progressive myoclonic, 8 11.9
38 epilepsy, familial temporal lobe, 2 11.9
39 febrile infection-related epilepsy syndrome 11.9
40 epilepsy, progressive myoclonic, 9 11.9
41 amish infantile epilepsy syndrome 11.9
42 pyridoxal 5'-phosphate-dependent epilepsy 11.9
43 epilepsy, familial focal, with variable foci 11.9
44 epilepsy, childhood absence 6 11.9
45 epilepsy, progressive myoclonic 1a 11.9
46 myoclonic-atonic epilepsy 11.9
47 dravet syndrome 11.9
48 epilepsy, idiopathic generalized 9 11.9
49 epilepsy, nocturnal frontal lobe, type 4 11.9
50 post-traumatic epilepsy 11.9

Graphical network of the top 20 diseases related to Epilepsy:



Diseases related to Epilepsy

Symptoms & Phenotypes for Epilepsy

UMLS symptoms related to Epilepsy:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, non-epileptic convulsion, seizures, focal, sleeplessness

GenomeRNAi Phenotypes related to Epilepsy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Resistant to vaccinia virus (VACV-A4L) infection GR00351-A-1 9.23 CACNB4 CSTB EFHC1 GABRA1 GRIN2A NHLRC1

MGI Mouse Phenotypes related to Epilepsy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 EFHC1 EPM2A GABBR1 GABRA1 GABRB3 GABRG2
2 growth/size/body region MP:0005378 10.21 CACNB4 CHRNB2 CSTB EPM2A GABBR1 GABRA1
3 mortality/aging MP:0010768 10.2 EPM2A GABBR1 GABRA1 GABRB3 GABRG2 LGI1
4 nervous system MP:0003631 10.16 CACNB4 CHRNA2 CHRNA4 CHRNB2 CLN8 CSTB
5 muscle MP:0005369 9.91 CACNB4 CHRNB2 CSTB EFHC1 EPM2A GABRA1
6 no phenotypic analysis MP:0003012 9.56 POLG SCN1B SLC2A1 CHRNA4 CSTB GABRA1
7 reproductive system MP:0005389 9.28 CACNB4 CLN8 GABBR1 GABRA1 GABRB3 GABRG2

Drugs & Therapeutics for Epilepsy

Drugs for Epilepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 524)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lacosamide Approved Phase 4,Phase 3,Phase 2,Phase 1 860352-01-8, 175481-36-4 219078
2
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
3
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
4
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
5
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
6
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 298-46-4 2554
7
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2 22316-47-8 2789
8
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2 1622-61-3 2802
9
Ethosuximide Approved Phase 4,Phase 3 77-67-8 3291
10
Felbamate Approved Phase 4 25451-15-4 3331
11
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
13
Nitrazepam Approved Phase 4,Phase 2 146-22-5 4506
14
Oxcarbazepine Approved Phase 4,Phase 3,Phase 2,Phase 1 28721-07-5 34312
15
Phenobarbital Approved Phase 4,Phase 3,Phase 2,Phase 1 50-06-6 4763
16
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 57-41-0 1775
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
18
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
19
Tiagabine Approved Phase 4,Phase 1 115103-54-3 60648
20
Vigabatrin Approved Phase 4,Phase 3,Phase 2 68506-86-5, 60643-86-9 5665
21
Zonisamide Approved, Investigational Phase 4,Phase 3 68291-97-4 5734
22 Piracetam Approved Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
23
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
24
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
25
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
26
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
27
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
28
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
29
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 159351-69-6 6442177
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
31
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
32
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
33
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
34
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
35
Citalopram Approved Phase 4 59729-33-8 2771
36
Ezogabine Approved Phase 4,Phase 3,Phase 2,Phase 1 150812-12-7 121892
37
Clevidipine Approved Phase 4 167221-71-8
38
Hydralazine Approved Phase 4 86-54-4 3637
39
Labetalol Approved Phase 4 36894-69-6 3869
40
Eslicarbazepine acetate Approved Phase 4,Phase 3,Phase 2,Phase 1 75970-99-9, 236395-14-5 123618
41
Sertraline Approved Phase 4,Phase 3 79617-96-2 68617
42
Acetaminophen Approved Phase 4 103-90-2 1983
43
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
44
Ibuprofen Approved Phase 4 15687-27-1 3672
45
Fosphenytoin Approved Phase 4,Phase 3,Phase 2,Phase 1 93390-81-9 56339
46
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
47
Memantine Approved, Investigational Phase 4 19982-08-2 4054
48
Bupropion Approved Phase 4,Phase 3 34841-39-9, 34911-55-2 444
49 Stiripentol Approved Phase 4,Phase 3,Phase 2 49763-96-4
50
Miglustat Approved Phase 4 72599-27-0 51634

Interventional clinical trials:

(show top 50) (show all 1480)
id Name Status NCT ID Phase
1 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
2 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
3 Cognitive and Behavioral Effects of Lacosamide Unknown status NCT01175954 Phase 4
4 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4
5 Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study Unknown status NCT00956696 Phase 4
6 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4
7 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4
8 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients Unknown status NCT02404168 Phase 4
9 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
10 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4
11 A Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4
12 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4
13 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4
14 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
15 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4
16 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4
17 Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study Unknown status NCT01935908 Phase 4
18 Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. Unknown status NCT01478035 Phase 4
19 Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Completed NCT00896987 Phase 4
20 Study on Migraine and Headache in Epileptic Patients Completed NCT00642564 Phase 4
21 Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin Completed NCT01128712 Phase 4
22 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Completed NCT01713777 Phase 4
23 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
24 RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy Completed NCT00564915 Phase 4
25 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study - Completed NCT02100644 Phase 4
26 Levetiracetam for Benign Rolandic Epilepsy Completed NCT00181116 Phase 4
27 Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy Completed NCT00043914 Phase 4
28 Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy Completed NCT00216567 Phase 4
29 Methylphenidate Treatment of Attention Deficits in Epilepsy Completed NCT02178995 Phase 4
30 Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: Completed NCT00356018 Phase 4
31 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Completed NCT00245713 Phase 4
32 Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy Completed NCT01214707 Phase 4
33 An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy Completed NCT01682681 Phase 4
34 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4
35 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4
36 Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy Completed NCT00264680 Phase 4
37 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Completed NCT01689649 Phase 4
38 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4
39 Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA) Completed NCT00302991 Phase 4
40 Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation Completed NCT00298818 Phase 4
41 Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency Completed NCT00684424 Phase 4
42 S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00630968 Phase 4
43 Study of Valproate in Young Patients Suffering From Epilepsy Completed NCT00385411 Phase 4
44 Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D Completed NCT02890823 Phase 4
45 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed NCT01498822 Phase 4
46 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed NCT00160654 Phase 4
47 A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy Completed NCT01030094 Phase 4
48 Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy Completed NCT00323947 Phase 4
49 A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Completed NCT00266604 Phase 4
50 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4

Search NIH Clinical Center for Epilepsy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: epilepsy

Genetic Tests for Epilepsy

Genetic tests related to Epilepsy:

id Genetic test Affiliating Genes
1 Epilepsy 24

Anatomical Context for Epilepsy

MalaCards organs/tissues related to Epilepsy:

39
Temporal Lobe, Brain, Testes, Cortex, Bone, Amygdala, Heart

Publications for Epilepsy

Articles related to Epilepsy:

(show top 50) (show all 6454)
id Title Authors Year
1
Pharmacists' knowledge of issues in pharmacotherapy of epilepsy using antiepileptic drugs: A cross-sectional study in Palestinian pharmacy practice. ( 28088050 )
2017
2
A critical assessment of the association between postnatal toxoplasmosis and epilepsy in immune-competent patients. ( 28083719 )
2017
3
Review and update of the Hong Kong Epilepsy Guideline on status epilepticus. ( 28057897 )
2017
4
Aberrant Expression of miR-323a-5p in Patients with Refractory Epilepsy Caused by Focal Cortical Dysplasia. ( 27824513 )
2017
5
New SMARCA2 mutation in a patient with Nicolaides-Baraitser syndrome and myoclonic astatic epilepsy. ( 27665729 )
2017
6
A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by Infantile Epilepsy, Cataracts, and Profound Developmental Delay. ( 28132692 )
2017
7
Genome-Wide DNA Methylation Patterns Analysis of Noncoding RNAs in Temporal Lobe Epilepsy Patients. ( 28058582 )
2017
8
Predictors and mechanisms of epilepsy occurrence in cerebral gliomas: What to look for in clinicopathology. ( 28087392 )
2017
9
Sudden unexpected death in epilepsy (SUDEP) disclosure in pediatric epilepsy: An Italian survey on "to tell or not to tell". ( 28088049 )
2017
10
Development and validation of the stigma scale for epilepsy in Turkey. ( 28092838 )
2017
11
Dynamic functional network connectivity in idiopathic generalized epilepsy with generalized tonic-clonic seizure. ( 27726245 )
2017
12
A Retrospective Analysis of Stereoelectroencephalography and Subdural Electroencephalography for Preoperative Evaluation of Intractable Epilepsy. ( 28088805 )
2017
13
Seizure-European Journal of Epilepsy at age 25: Where are we now and where we are going? ( 28089271 )
2017
14
Immunohistochemical study of Metallothionein in patients with temporal lobe epilepsy. ( 28087193 )
2017
15
Exome sequencing identifies a novel homozygous CLN8 mutation in a Turkish family with Northern epilepsy. ( 27844444 )
2017
16
BRAF V600E mutation in epilepsy-associated glioneuronal tumors: Prevalence and correlation with clinical features in a Chinese population. ( 27984807 )
2017
17
Nodding syndrome, other forms of epilepsy, and the Nakalanga syndrome most likely directly or indirectly caused by Onchocerca volvulus. ( 27745691 )
2017
18
A Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic Information. ( 28052106 )
2017
19
Antioxidant polymorphisms do not influence the risk of epilepsy or its drug resistance after neonatal hypoxic-ischemic brain injury. ( 28222320 )
2017
20
Second monotherapy in childhood absence epilepsy. ( 27986874 )
2017
21
Altered Expression of CXCL13 and CXCR5 in Intractable Temporal Lobe Epilepsy Patients and Pilocarpine-Induced Epileptic Rats. ( 27873133 )
2017
22
Epilepsy-associated gene Nedd4-2 mediates neuronal activity and seizure susceptibility through AMPA receptors. ( 28212375 )
2017
23
Female sexual function mediates the effects of medication adherence on quality of life in people with epilepsy. ( 28088682 )
2017
24
The influence of patient, caregiver, and family factors on symptoms of anxiety and depression in children and adolescents with intractable epilepsy. ( 28088680 )
2017
25
Rabies Tracing of Birthdated Dentate Granule Cells in Rat Temporal Lobe Epilepsy. ( 28470680 )
2017
26
Phosphoglycerate dehydrogenase (PHGDH) deficiency without epilepsy mimicking primary microcephaly. ( 28440900 )
2017
27
Lack of heart rate variability during sleep-related apnea in patients with temporal lobe epilepsy (TLE)-an indirect marker of SUDEP? ( 28091857 )
2017
28
Severe intermittent anxiety attacks. A diagnosis challenge in temporal lobe epilepsy. ( 28064331 )
2017
29
Incidence and predictors of epilepsy after pediatric arterial ischemic stroke. ( 28087825 )
2017
30
Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy. ( 28251733 )
2017
31
Neuropsychological outcome following frontal lobectomy for pharmacoresistant epilepsy in adults. ( 28087827 )
2017
32
A career in epilepsy. ( 28089367 )
2017
33
Sex differences in verbal and nonverbal learning before and after temporal lobe epilepsy surgery. ( 28033547 )
2017
34
Epilepsy in hemiplegic migraine: Genetic mutations and clinical implications. ( 28058944 )
2017
35
Patterns of Gray Matter Abnormalities in Idiopathic Generalized Epilepsy: A Meta-Analysis of Voxel-Based Morphology Studies. ( 28060866 )
2017
36
The transition from pediatric to adult care for youth with epilepsy: Basic biological, sociological, and psychological issues. ( 28089368 )
2017
37
Stereo electroencephalography-guided radiofrequency thermocoagulation (SEEG-guided RF-TC) in drug-resistant focal epilepsy: Results from a 10-year experience. ( 27859033 )
2017
38
Determination of SCN1A genetic variants in Mexican patients with refractory epilepsy and Dravet syndrome. ( 28525652 )
2017
39
Epilepsy and electroencephalographic abnormalities in C9orf72 repeat expansion. ( 27652840 )
2017
40
Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. ( 28315807 )
2017
41
Role of dietary and lifestyle modifications in reflex epilepsy based on traditional Persian medicine. ( 28088254 )
2017
42
Visually evoked startle response in a patient with epilepsy: a case report and review of the literature. ( 28090805 )
2017
43
Associations between MDR1 C3435T polymorphism and drug-resistant epilepsy in the Polish population. ( 27534401 )
2017
44
Preoperative automated fibre quantification predicts postoperative seizure outcome in temporal lobe epilepsy. ( 28031219 )
2017
45
Novel homozygous missense variant of GRIN1 in two sibs with intellectual disability and autistic features without epilepsy. ( 28051072 )
2017
46
Bursts of seizures in long-term recordings of human focal epilepsy. ( 28084639 )
2017
47
Navigation-assisted trans-inferotemporal cortex selective amygdalohippocampectomy for mesial temporal lobe epilepsy; preserving the temporal stem. ( 28067149 )
2017
48
Features of stimulus-specific seizures in dogs with reflex epilepsy: 43 cases (2000-2014). ( 28001116 )
2017
49
Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. ( 27900402 )
2017
50
Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s. ( 28089286 )
2017

Variations for Epilepsy

Copy number variations for Epilepsy from CNVD:

7 (show top 50) (show all 613)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13367 1 1 16700000 Deletion Epilepsy
2 17286 1 142400000 148000000 Deletion Epilepsy
3 17377 1 142600000 147000000 Deletion Epilepsy
4 18328 1 145000000 145900000 Deletion GJA8 Epilepsy
5 33187 1 43391045 43424847 Deletion SLC2A1 Epilepsy
6 36112 1 72040000 72150000 Deletion NEGR1 Epilepsy
7 41452 10 18271821 21110683 Deletion Epilepsy
8 43051 10 43288081 55324785 Duplication Epilepsy
9 43386 10 46384979 51265056 Duplication Epilepsy
10 43763 10 49062854 52062367 Duplication Epilepsy
11 44157 10 52900000 61200000 Deletion Epilepsy
12 44656 10 61200000 64800000 Duplication Epilepsy
13 44657 10 61200000 64800000 Microdeletion Epilepsy
14 64691 12 130430446 131708300 Duplication Epilepsy
15 66574 12 3100000 10000000 Deletion Epilepsy
16 67699 12 4408710 5978830 Microdeletion AKAP3 Epilepsy
17 67700 12 4408710 5978830 Microdeletion C12orf4 Epilepsy
18 67701 12 4408710 5978830 Microdeletion DYRK4 Epilepsy
19 67702 12 4408710 5978830 Microdeletion FGF6 Epilepsy
20 67703 12 4408710 5978830 Microdeletion GALNT8 Epilepsy
21 67704 12 4408710 5978830 Microdeletion KCNA1 Epilepsy
22 67705 12 4408710 5978830 Microdeletion KCNA5 Epilepsy
23 67706 12 4408710 5978830 Microdeletion KCNA6 Epilepsy
24 67707 12 4408710 5978830 Microdeletion NDUFA9 Epilepsy
25 67708 12 4408710 5978830 Microdeletion NTF3 Epilepsy
26 67709 12 4408710 5978830 Microdeletion RAD51AP1 Epilepsy
27 67710 12 4408710 5978830 Microdeletion TMEM16B Epilepsy
28 67711 12 4408710 5978830 Microdeletion VWF Epilepsy
29 80132 13 84690000 85360000 Deletion SLITRK6 Epilepsy
30 81544 14 103375996 106312055 Deletion Epilepsy
31 83035 14 19100000 34100000 Duplication FOXG1 Epilepsy
32 83208 14 19508845 34063670 Gain Epilepsy
33 83228 14 19582682 29076500 Gain Epilepsy
34 83231 14 19582682 33275612 Gain Epilepsy
35 84310 14 26908812 30254928 Gain Epilepsy
36 84331 14 27474978 30603041 Gain Epilepsy
37 84363 14 28217364 34635622 Gain Epilepsy
38 84366 14 28257153 35048345 Gain Epilepsy
39 87172 14 70960000 71230000 Deletion SIPA1L1 Epilepsy
40 89268 15 17000000 31400000 Deletion-maternal Epilepsy
41 89270 15 17000000 31400000 Deletion-paternal Epilepsy
42 89276 15 17000000 31400000 Duplication Epilepsy
43 89372 15 18285782 20868229 Microdeletion A26B1 Epilepsy
44 89373 15 18285782 20868229 Microdeletion AC025884.28 Epilepsy
45 89374 15 18285782 20868229 Microdeletion AC026495.13 Epilepsy
46 89375 15 18285782 20868229 Microdeletion AC091565.10 Epilepsy
47 89376 15 18285782 20868229 Microdeletion AC116165.7 Epilepsy
48 89377 15 18285782 20868229 Microdeletion AC126335.16 Epilepsy
49 89378 15 18285782 20868229 Microdeletion AC126603.9 Epilepsy
50 89379 15 18285782 20868229 Microdeletion AC127381.4 Epilepsy

Expression for Epilepsy

Search GEO for disease gene expression data for Epilepsy.

Pathways for Epilepsy

Pathways related to Epilepsy according to GeneCards Suite gene sharing:

(